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Coronary artery bypass surgery (CABG) is still one of the most frequently performed 
surgical procedures all over the world. The results of this procedure have been con-
stantly improved over the years with low perioperative mortality rates, with relatively low 
complication rates. To further improve these outstanding results, the clinicians focused 
their attention at biomarkers as outcome predictors. Although biological testing for 
disease prediction has already been discussed many times, the role of biomarkers in 
outcome prediction after CABG is still controversial. In this article, we reviewed the cur-
rent knowledge regarding the role of genetic and dynamic biomarkers and their possible 
association with the occurrence of adverse clinical outcomes after CABG. We also took 
into consideration that the molecular pathway activation and the possible imbalance 
may affect hard outcomes and graft patency. We analyzed biomarkers classified in two 
different categories depending on their possibility to change over time: genetic mark-
ers and dynamic markers. Moreover, we evaluated these markers by dividing them, 
into sub-categories, such as inflammation, hemostasis, renin–angiotensin, endothelial 
function, and other pathways. We showed that biomarkers might be associated with 
unfavorable outcomes after surgery, and in some cases improved outcome prediction. 
However, the identification of a specific panel of biomarkers or of some algorithms includ-
ing biomarkers is still in an early developmental phase. Finally, larger studies are needed 
to analyze broad panel of biomarkers with the specific aim to evaluate the prediction of 
hard outcomes and graft patency.
Keywords: coronary artery bypass, biomarkers, genetic, dynamic, outcome
iNTRODUCTiON
According to the European guidelines, coronary artery bypass surgery (CABG), which was intro-
duced in the late sixties, associated with percutaneous intervention (PCI) is still one of the most 
frequently performed surgical procedures. CABG is still demonstrated to improve early-, mid-, and 
long-term results as regards event-free survival. Therefore, when patients are in elective surgery or 
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the lesion is not treatable by PCI, CABG remains the treatment 
of choice not only in the case of left main trunk disease, reduced 
cardiac function or severe coronary disease (1, 2), but also in the 
case of diabetes (3, 4) and in the majority of patients affected by 
three-vessel disease (5, 6). Even if there have been complex clini-
cal features of patients eligible for CABG, the early results of this 
procedure have been constantly improved over the years with low 
perioperative mortality rates, with relatively low complication 
rates [i.e., myocardial infarction (MI), stroke, and renal failure 
requiring dialysis (7–9)].
However, CABG gives rise to an important and sustained 
activation of different molecular pathways and cellular compo-
nents. This leads to a persisting systemic inflammatory response 
associated with the activation of the hemostatic systems, with the 
concurrent occurrence of endothelial dysfunction and oxidative 
stress damage (10, 11).
It is well known that the incidence of adverse cardiovascular 
events, such as cardiac death, MI, stroke, graft occlusion and 
need for additional revascularization procedures, albeit relatively 
low in terms of numbers, can occur in the early days, weeks, 
and, subsequently, months after surgery (12–14). This could be 
explained by the activated molecular mechanisms in the periop-
erative period and in the early follow-up of CABG [i.e., pathways 
related to homeostasis and inflammation (15, 16)]. Moreover, a 
number of hereditary variables, in association with classic risk 
factors, might also be responsible for adverse events, suggesting a 
potential role of some gene polymorphisms.
In this article, we reviewed the current knowledge on molecu-
lar mechanisms and the association of biomarkers in the occur-
rence of adverse clinical outcomes after CABG, with a special 
emphasis on pathway activation and imbalance that may affect 
hard outcomes and graft patency.
BiOMARKeRS AND OUTCOMe 
PReDiCTiON?
Several translational studies have tried to address the question 
concerning the possible role of biological markers, and their 
underlying molecular mechanisms, in the prediction of major 
complications (graft patency included) after CABG.
Biomarkers should be divided into two different categories, 
depending on their possibility to change over time into (1) genetic 
markers, stable over time, and (2) dynamic markers, which may 
change mainly over time, but not only, perioperatively. In the next 
chapters, we examined the role of different biomarkers following 
this scheme.
GeNeTiC MARKeRS
Gene polymorphisms and/or genetic mutations as new markers 
of morbidity and mortality in patients after CABG have been 
intensively studied over the past few years (17). Numerous stud-
ies in this field have been based on the identification of single 
nucleotide polymorphisms (SNPs) in candidate genes regulating 
inflammatory response (18, 19), thrombotic pathways (20, 21), 
oxidative stress (11), renin–angiotensin system (22, 23), cell 
damage (24, 25), and their association with post-operative results 
in patients undergoing CABG. The studies published so far and 
described in Tables S1–S5 in Supplementary Material based on 
specific pathways, have addressed two main questions: (1) can 
gene polymorphisms or mutations modulate or affect plasma lev-
els of a dynamic biomarker, both at baseline or after the stimulus 
resulting from cardiac surgery? (2) can gene polymorphisms 
or mutations be associated with peri- and long post-operative 
outcomes?
inflammation
What emerges from currently available studies on inflammation 
is that gene polymorphisms may play a role in the modulation 
of some markers, such as IL-6 (18, 19, 26, 27), CRP (26–29), and 
TNF-α (30) (Table S1 in Supplementary Material). Moreover, 
they affect the levels of different biomarkers not only preoperative 
but also intra- and post-operative. In addition, there are other 
studies with limited sample size that need further evidence, sug-
gesting a possible association between genetic polymorphisms 
and outcomes, such as the role of IL-6 (31) and CRP (31) genes 
in perioperative MI. Finally, the PEGASUS study, with a relatively 
large number of CABG patients, assessed the role of different cat-
egories of gene polymorphisms in association with the outcomes 
after CABG (20). This study showed that SNPs associated with 
inflammatory molecules [CRP, IL-1α, IL-1β, IL-6, IL-8, IL-10, 
interleukin 1 receptor antagonist (IL-1RN), and TNFα] did not 
affect long-term survival after CABG.
Hemostasis
The same observation seems to be true for some of the hemostasis 
markers (Table S2 in Supplementary Material). However, we have 
reliable data regarding two markers: fibrinogen (23, 27), which is 
between inflammation and hemostasis; and beta-thromboglob-
ulin (21). Interestingly, only one study has addressed the main 
issue of graft patency after CABG by assessing the presence of 
factor V Leiden genetic mutations (22). This study, limited by 
the small number of patients enrolled (a total of 100 CABGs), 
has suggested that the mutation Arg506Gln tends to be associated 
with saphenous graft occlusion [5/11 (45%) carriers vs. 18/89 
(20%) non-carriers, p = 0.06] (32). Unfortunately, other studies 
on this subject analyzed only 2-year all causes mortality finding 
no associations (33), thus leaving the question on genetic bases 
of bypass patency open.
Renin–Angiotensin
Regarding the renin–angiotensin system, most studies focused 
their attention on the gene coding for the angiotensin-converting 
enzyme (ACE; Table S3 in Supplementary Material). A study 
conducted by Welsby et  al. (23) investigated and showed that 
ACE insertion/deletion (I/D) polymorphism plays a role in 
post-operative bleeding. On the contrary, the association of ACE 
I/D with cardiac mortality or all-cause mortality is controversial 
(22, 34). The large PEGASUS study showed no association with 
5-year all-cause mortality (20), while a smaller study carried out 
by Völzke et al. (35) showed a strong association with both 2-year 
all-cause and cardiac mortality.
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endothelial Function
There are other studies with limited sample size that need further 
evidence, suggesting a possible association between genetic 
polymorphisms and outcomes, such as the role of intercellular 
adhesion molecule-1 (ICAM-1) and of E-selectin 24 genes in 
perioperative MI (31, 36) (Table S4 in Supplementary Material). 
On the contrary, the PEGASUS study related to the endothelial 
function polymorphisms did not find any association between 
E-selectin, ICAM1, NOS3, PECAM1 VCAM1 SNPs, and 5-year 
all-cause mortality (20, 37).
Other Pathways
Finally, there is also evidence suggesting that the post-operative 
levels of cell damage biomarker, cardiac Troponin-I, are affected 
by genetic variations. These occur in the chromosome 9 region 
p21 locus (24), suggesting a possible association between genetic 
profile and the risk of perioperative MI (Table S5 in Supplementary 
Material). This genetic variation (rs 10116277), which is adjacent 
or within genes involved in apoptosis, cell senescence, and cell 
cycle, significantly influences all-cause mortality at 5 years after 
CABG. This genetic variation has been demonstrated to substan-
tially improve the predictive performance of the EuroSCORE 
risk algorithm (25). Moreover, together with two other variants 
found on the same chromosome region, it may also predict the 
occurrence of perioperative MI (24).
However, the studies reported in Tables S1–S5 in 
Supplementary Material have demonstrated and support the role 
of some genetic polymorphisms in the determination of plasma 
levels of some biomarkers. On the other hand, studies aim at 
demonstrating a possible relation between genetic variants and 
outcomes, such as mortality, stroke, or MI, failed so far because 
are seldom adequately powered to their scope. Thus, as regards 
current knowledge, there is not enough data to support or exclude 
such associations.
DYNAMiC MARKeRS
The behavior of what we call “dynamic” markers has been fre-
quently assessed in the previous years in relation with periopera-
tive outcomes. It is much easier to identify a marker represented 
by a continuous variable (e.g., CRP) as a potential independent 
predictor of a perioperative outcome itself compared to a 
categorical one (e.g., the presence of a genetic polymorphism). 
This is especially true in the case of low incidence rates. In the 
case of hard outcomes after CABG, the sample size to achieve 
a statistically significance may be excessively large. Moreover, 
since a number that can change over time represents dynamic 
markers, the correct timing for the assessment of the marker 
needs to be taken into consideration. In other words, not only the 
preoperative levels of the biomarker can be predictive of outcome 
but also the changes occurring perioperatively. The biomarkers 
much more frequently assessed in relation to outcome prediction 
belong mainly to inflammatory and hemostatic pathways.
inflammation
Inflammatory biomarkers have been frequently studied to assess 
their effect on early and long-term mortality, whereas hemostatic 
ones have been evaluated for their possible role in the occurrence 
of post-operative graft occlusion. As regards inflammatory path-
ways, several studies have shown that even non-specific inflam-
matory markers such as preoperative leukocyte count and CRP 
can predict in-hospital (38–41), mid- and long-term mortality 
after CABG (39, 42). Moreover, some small studies suggest that, 
besides mortality, increasing baseline CRP levels can also be an 
independent predictor both of early (43) and of late (44) major 
post-operative complications and that CRP levels may also play 
a role in early graft occlusion (45). In addition, IL-6 has been 
shown to predict the occurrence of early post-operative compli-
cations after surgery (19, 45, 46), such as early graft failure (45). 
Unfortunately, no information is currently available on the poten-
tial predictive power of the perioperative levels of both markers, 
and this could be of major interest as it is well known that they are 
both substantially unaffected by the use or the avoidance of the 
roller pump (47, 48). In this specific context, this feature could be 
important as these markers, in a near future, could become more 
reliable outcome predictors for CABG, whatever the technique 
chosen by the surgeon.
Hemostatis
Concerning hemostasis, several different biomarkers have been 
assessed to predict perioperative bleeding and subsequent 
transfusion needs. Among them, preoperative fibrinogen (49, 
50) and platelet aggregation impairment (51) have been associ-
ated with increased perioperative bleeding and transfusion risk. 
Interestingly, preoperative fibrinogen levels have a more predictive 
significance in women compared to men. It is known that women 
are at high risk for the need of perioperative blood transfusions 
(52) and previous interesting findings suggest that some degree 
of gender difference exists which may need further investigation 
(49). Other studies have also demonstrated that there might be a 
potential role for the changes of hemostatic biomarkers that occur 
perioperatively, thereby showing, once again, that perioperative 
levels of fibrinogen (up to 24 h after surgery) may affect bleeding.
Another important molecule involved in the hemostatic path-
way is antithrombin III, a small protein that inactivates several 
enzymes of the coagulation system.
The levels of antithrombin III when measured upon Intensive 
Care Unit (ICU) arrival are predictive of several perioperative 
complications such as revision for bleeding, prolonged ICU and 
hospital stay, prolonged ventilation, neurological and thrombotic 
complications, blood transfusions (53, 54).
In our opinion, both fibrinogen and antithrombin levels are 
strictly associated with the consumption of the coagulation fac-
tors that occurs during surgery. As far as we know, the complexity 
of surgery and perfusion time changes this consumption, making 
it difficult to clarify the primary role of these two biomarkers. In 
other words, we consider it quite impossible to clarify the old 
concept of “who came first: the chicken or the egg?,” i.e., whether 
the primum movens is due to the decrease in levels of antithrom-
bin itself or to the features and complexity of surgery that cause 
a decrease in antithrombin. Finally, some studies have also 
addressed the role of hemostatic perturbations and graft occlu-
sion. These studies suggest that preoperative levels of thrombin 
generation markers (prothrombin fragment 1 + 2) (55) as well as 
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fibrinolysis markers (tissue polypeptide antigen – tPA and anti-
hemophilic factor VIII) (56) might be associated with reduced 
early graft patency. In addition, post-operative analysis (between 
1 and 7 post-operative days) revealed the association between 
graft occlusion and increased activity of fibrinolytic marker PAI-1 
(57, 58), increased levels of the thrombin generation marker 
(thrombin–antithrombin complexes) (56) and fibrinogen (56).
However, all these data should be taken with extreme cau-
tion as most of the studies were performed on a limited number 
of patients. The limited number of patients enrolled could be 
explained by their reluctance to undergo repeated coronary 
angiography after surgery, as most of these studies were per-
formed before coronary computed tomography (CT) became 
available.
In the coming years, we expect that more studies will address 
the problem of graft patency after CABG, as coronary CT scan 
may favor patency assessment, thereby avoiding all the problems 
related to coronary angiography. In line with this latter statement, 
there is a novel study that was recently published from a sub-
analysis of the radial patency study at 5-year follow-up (59). In 
this nested case–control sub-study, 87 patients were reassessed 
via coronary angiography or coronary CT scan at an average 
follow-up time of 8 ± 1.1 years after surgery. Twenty-six patients 
had an occluded radial or saphenous vein graft, whereas 61 
did not. The analysis of fibrinogen levels showed that elevated 
levels of this molecule are associated with graft occlusion (59). 
However, the strength of this finding is sensibly weakened by the 
fact that blood collection was only done at the time of coronary 
angiography or CT scan, thus limiting the potential predictive 
role of fibrinogen itself.
All these data demonstrate that current knowledge about the 
role of biomarkers is still limited to the prognostic ability of some 
inflammation markers, mainly represented by CRP and to a lesser 
extent by IL-6. In conclusion, hemostatic markers have a definite 
role in perioperative bleeding and a much less definite role in 
hard outcomes and in graft patency.
CONCLUSiON
Current available data suggest that both genetic and dynamic 
markers may have a substantial correlation with outcomes. 
At present, it is too early to draw conclusions about the role of 
biomarkers on graft patency over time, but in the near future new 
technologies will be of great help.
What we know is that after coronary bypass surgery, there is a 
marked and protracted activation of several molecular pathways 
indicating increased inflammatory status, hemostasis activation, 
as well as increased oxidative stress and unfavorable endothelial 
milieu. This review has shown that biomarkers are associated with 
unfavorable outcomes after surgery. We hope that more clinicians 
and researchers will focus their attention to discover if these asso-
ciations can be of help in the prediction of outcomes. Moreover, 
changes in dynamic markers that occur at a perioperative phase 
may, in some cases, have a strong correlation with post-operatory 
outcome. However, a panel of biomarkers should be identified in 
order to help the clinician in the assessment of early and late risk 
of negative outcomes after the intervention. In addition, studies 
should be carried out on the link between these markers and the 
identification of the underlying molecular mechanisms, which 
can become the objective for targeted therapies. In our opinion, 
translational cardiovascular research needs to fill the gap between 
molecular mechanisms and a mere biomarker evaluation.
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